Table 1.
Study and patient characteristics.
| Study | Year of publication, Journal | Patients (n) | Male (%) | Gestational age at birth (weeks) | Postnatal age at start of sildenafil (weeks) | Initial PAP (mmHg) | Initial sildenafil dose (mg/kg/day) | Maximum sildenafil dose (mg/kg/day) | Median sildenafil dose (mg/kg/day) |
|---|---|---|---|---|---|---|---|---|---|
| Mourani et al.30 | 2009, Journal of Pediatrics | 18 | 60.9 | 28.0 ± 4.5 | 26.3 ± 22.1 | NR | 1.5 | 8.0 | NR |
| Nyp et al.31 | 2012, Journal of Perinatology | 21 | 54.5 | 27.0 ± 2.5 | 23.9 ± 8.0 | 65.0 ± 15.5 | 0.3–0.5 | 6.0 | NR |
| Tan et al.32 | 2015, European Journal of Pediatrics | 22 | 57.1 | 25.6 ± 1.3 | 24.1 ± 9.8 | 56.5 ± 10.4 | 0.8 | 6.0 | NR |
| Trottier-Boucher et al.33 | 2015, Pediatric Cardiology | 23 | 77.8 | 26.0 ± 2.2 | 15.1 ± 9.0 | NR | 1.0 | 7.3 | 4.4 ± 1.5 |
| Kadmon et al.29 | 2016, Pediatric Pulmonology | 17 | 45.0 | 25.0 ± 2.0 | 20.9 ± 26.1 | 32.0 ± 3.8 (n = 8) | NR | 8.0* | 3.0 |
| Pooled total† | 101 | 59.1 | 26.3 ± 2.7 | 21.9 ± 15.9 |
Results are given in mean (±SD).
*
Following the FDA warning in August 2012 regarding high-dose sildenafil use in pediatric PH, the dose was reduced to 1 mg/kg/dose in all patients.
†
Sample size weighting.
PAP, pulmonary arterial pressure; NR, variable not reported.